What one share of FibroBiologics holds
We are a clinical-stage biotechnology company focused on developing and commercializing fibroblast-based therapies for patients suffering from chronic diseases with significant unmet medical needs, including wound healing, multiple sclerosis, or MS, degenerative disc disease, psoriasis, certain cancers, and potential human longevity applications including thymic involution reversal using a thymic organoid.
FibroBiologics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$4.78 |
|---|---|
| Capex (buildings and equipment) | $0.00 |
| Free cash flow | −$3.90 |
| Cash and investments | $0.53 |
| Book value | $0.70 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2022 | — | −$3.63 | — | — | — | −$2.83 |
| 2023 | — | −$13.50 | $0.35 | −$4.89 | — | $0.77 |
| 2024 | — | −$6.79 | $0.11 | −$7.35 | — | $1.45 |
| 2025 | — | −$8.35 | $0.12 | −$7.46 | — | $1.82 |
Common questions about FibroBiologics
How much does one share of FibroBiologics earn?
Over the last 12 months, FibroBiologics lost $4.78 for each share.
Does FibroBiologics pay a dividend?
FibroBiologics didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is FibroBiologics’s book value per share?
FibroBiologics’s book value is $0.70 per share: what would be left for each share if it sold everything at the values on its books and paid every debt, as of June 30, 2026.
How much cash and debt does each share of FibroBiologics have?
Each share of FibroBiologics has $0.53 of cash and investments, as of June 30, 2026.
What is FibroBiologics’s free cash flow per share?
−$3.90 per share over the last 12 months. Free cash flow is the cash left over after spending on buildings and equipment.
Has FibroBiologics bought back shares?
FibroBiologics’s share count rose about 58% from 2022 to 2025. That dilution means each share owns a smaller slice of the company.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.